It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Streptomyces are Gram-positive bacteria of significant industrial importance due to their ability to produce a wide range of antibiotics and bioactive secondary metabolites. Recent advances in genome mining have revealed that Streptomyces genomes possess a large number of unexplored silent secondary metabolite biosynthetic gene clusters (smBGCs). This indicates that Streptomyces genomes continue to be an invaluable source for new drug discovery. Here, we present high-quality genome sequences of 22 Streptomyces species and eight different Streptomyces venezuelae strains assembled by a hybrid strategy exploiting both long-read and short-read genome sequencing methods. The assembled genomes have more than 97.4% gene space completeness and total lengths ranging from 6.7 to 10.1 Mbp. Their annotation identified 7,000 protein coding genes, 20 rRNAs, and 68 tRNAs on average. In silico prediction of smBGCs identified a total of 922 clusters, including many clusters whose products are unknown. We anticipate that the availability of these genomes will accelerate discovery of novel secondary metabolites from Streptomyces and elucidate complex smBGC regulation.
Measurement(s) | DNA • genome • sequence_assembly • sequence feature annotation |
Technology Type(s) | DNA sequencing • sequence assembly process • sequence annotation |
Factor Type(s) | strain |
Sample Characteristic - Organism | Streptomyces |
Machine-accessible metadata file describing the reported data:
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Korea Advanced Institute of Science and Technology, Department of Biological Sciences and KI for the BioCentury, Daejeon, Republic of Korea (GRID:grid.37172.30) (ISNI:0000 0001 2292 0500)
2 University of California San Diego, Department of Bioengineering, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California San Diego, Department of Pediatrics, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Technical University of Denmark, Novo Nordisk Foundation Center for Biosustainability, Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870)
3 Korea Advanced Institute of Science and Technology, Department of Biological Sciences and KI for the BioCentury, Daejeon, Republic of Korea (GRID:grid.37172.30) (ISNI:0000 0001 2292 0500); Intelligent Synthetic Biology Center, Daejeon, Republic of Korea (GRID:grid.37172.30); Technical University of Denmark, Novo Nordisk Foundation Center for Biosustainability, Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870)